

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 37

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

PC 2220

57959B

<p>Licensee</p> <p>1. Clark Memorial Hospital</p> <p>2. 1220 Missouri Avenue Jeffersonville, Indiana 47130</p>	<p>In accordance with letter dated December 10, 2012,</p> <p>3. License No. 13-12367-01 is amended in its entirety to read as follows:</p> <p>4. Expiration Date: October 31, 2014</p> <p>5. Docket No. 030-01658 Reference No.</p>
--------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. Not to exceed 1 curie
D. Iodine-125 permitted by 10 CFR 35.400	D. Sealed source (Bard Brachytherapy Model No. STM-1251)	D. 1 curie
E. Palladium-103 permitted by 10 CFR 35.400	E. Sealed source (Theragenics Model No. 200)	E. 1 curie
F. Any byproduct material permitted by 10 CFR 31.11	F. Prepackaged kits	F. 2 millicuries
G. Strontium-90	G. Sealed source (Tracerlab Model RA-2A)	G. One source not to exceed 100 millicuries

9. Authorized Use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging or localization study permitted by 10 CFR 35.200.
 - C. Any therapy procedure permitted by 10 CFR 35.300.
 - D. and E. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
 - F. *In vitro* studies.
 - G. For possession only, incident to disposal.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.
13-12367-01

Docket or Reference No.
030-01658

Amendment No. 37

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 1220 Missouri Avenue, Jeffersonville, Indiana.
11. **Radiation Safety Officer (RSO): Damion Hazlett, M.D.**
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical uses:

<u>Authorized User</u>	<u>Material and Use</u>
Mohammed Hussain, M.D.	10 CFR 35.100 and 35.200.
Dolph Martel Denny, M.D.	10 CFR 35.100 and 35.200.
William R. Fortner, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Edsel S. Reed, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Anthony Duncan, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11
Kelly J. Colomb, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11
Bapineedu Gondi, M.D.	10 CFR 35.100 and 35.200.
Gary Yurow, M.D.	10 CFR 35.100 and 35.200.
Koduvathara James, M.D.	10 CFR 35.100 and 35.200.
Carl E. Dillman, M.D.	10 CFR 35.100 and 35.200.
D. Mark Bickers, M.D.	10 CFR 35.100 and 35.200.
Wayne Shugoll, M.D.	10 CFR 35.100 and 35.200.
Armand Rothschild, M.D.	10 CFR 35.100 and 35.200.
Gurbachan Sohi, M.D.	10 CFR 35.100 and 35.200.
Sohail Ikram, M.D.	10 CFR 35.100 and 35.200.
Thomas Matthew Sweat, M.D.	10 CFR 35.100 and 35.200.
William J. Schoen, M.D.	10 CFR 35.100 and 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.
13-12367-01

Docket or Reference No.
030-01658

Amendment No. 37

<u>Authorized User</u>	<u>Material and Use</u>
John Terrence Kenny, M.D.	10 CFR 35.100 and 35.200.
Frederick Albrink, M.D.	10 CFR 35.300 and 35.400.
Zaka Ur Rahman, M.D.	10 CFR 35.100 and 35.200.
Craig S. Kamen, M.D.	10 CFR 35.100, 35.200 and 35.300.
F. Baby Jose, M.D.	10 CFR 35.400.
Mark Cornett, M.D.	10 CFR 35.400.
Mark Jones, M.D.	10 CFR 35.400.
Zulfiquar Bhatti, M.D.	10 CFR 35.100 and 35.200.
Brian Worm, M.D.	10 CFR 35.100, 35.200 and 35.300.
Ali Nawab Risvi, M.D.	10 CFR 35.100 and 35.200.
Geoffrey Peters, M.D.	10 CFR 35.100 and 35.200.
Srinivasarao Manchikalapudi, M.D.	10 CFR 35.100 and 35.200.
Kendall Goldschmidt, M.D.	10 CFR 35.100 and 35.200 and 35.300.
Christopher J. Day, M.D.	10 CFR 35.100 and 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma).
Thomas C. Passo, M.D.	10 CFR 35.100 and 35.200.
Naresh Solankhi, M.D.	10 CFR 35.100 and 35.200.
Naveen Devabhaktuni, M.D.	10 CFR 35.100 and 35.200.
Mitchell Jay Kline, M.D.	10 CFR 35.100 and 35.200.
Jerome Schrodt, M.D.	10 CFR 35.100, 35.200 and oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries.
Richard Eickler, M.D.	10 CFR 35.100 and 35.200.
Kevin P. Serey, M.D.	10 CFR 35.100, 35.200 and 35.300 limited to oral administration of sodium iodide-131.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.

13-12367-01

Docket or Reference No.

030-01658

Amendment No. 37Authorized UserMaterial and Use

David P. Musich, M.D.	10 CFR 35.300, 35.400 and 31.11.
Larry M. Leslie, M.D.	10 CFR 35.100 and 35.200.
Paul J. Rogers, M.D.	10 CFR 35.100 and 35.200.
Andrea Walker, D.O.	10 CFR 35.100, 35.200 and 35.300 limited to oral administration of sodium iodide-131.
Barbara Pawley, M.D.	10 CFR 35.100, 35.200 and 35.300 limited to oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries.
Emily Folz, M.D.	10 CFR 35.100, 35.200 and 35.300 limited to oral administration of sodium iodide-131.
Wayne St. Michael Gibson, M.D.	10 CFR 35.200.
Syed Raza, M.D.	10 CFR 35.200.
Anil K. Sharma, M.D.	10 CFR 35.200.
Mio Michael Stikovac, M.D.	10 CFR 35.200.
Steve Filardo, M.D.	10 CFR 35.100 and 35.200.
Bart Dawson, M.D.	10 CFR 35.100 and 35.200.
Ibrahim Fahsah, M.D.	10 CFR 35.100 and 35.200.
Igor Singer, M.D.	10 CFR 35.100 and 35.200.
Rodney A. Samaan, M.D.	10 CFR 35.200.
David Damion Hazlett, M.D.	10 CFR 35.100, 35.200 and 35.300 limited to oral administration of sodium iodide-131.
Don Stacy, M.D.	10 CFR 35.300

13. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.
13-12367-01Docket or Reference No.
030-01658**Amendment No. 37**


15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated April 22, 2004; and,
 - B. Letter received October 21, 2004; and
 - C. Letter dated October 17, 2008 and June 7, 2010.

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Date

FEB 04 2013

By

Toye L. Simmons
Materials Licensing Branch
Region III